查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736766

2026 年至 2032 年早产和胎膜早破检测市场（按检测类型、最终用户和地区划分）

Preterm Birth and PROM Testing Market by Test Type (Preterm Birth Tests, PROM Tests), End-User (Hospitals, Diagnostics Laboratories), & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

早产和胎膜早破检测市场评估—2026-2032

早产和胎膜早破 (PROM) 检测市场专注于早产和胎膜早破的诊断和治疗。早产率的上升和诊断技术的进步推动了这个市场的成长。随着人们越来越意识到医疗保健的重要性，这个新兴市场正在蓬勃发展。因此，市场规模预计在 2024 年将超过 23.9 亿美元，并在 2032 年达到约 41.1 亿美元的估值。

该市场正在开发用于早期检测和管理的新型检测方法。非侵入性操作和照护现场诊断正在定义未来。随着医疗保健专业人员努力改善患者预后并预防早产问题，对准确快速观察的需求正在推动市场成长。对早产和胎膜早破（PROM）检测的需求不断增长，使得市场在2026-2032年间的复合年增长率达到7.76%。

早产和胎膜早破检测市场定义/概述

早产是指怀孕37週前分娩，可能导致婴儿健康併发症。胎膜早破（PROM）检测：评估胎膜早破（PROM，即分娩开始前羊膜囊破裂）有助于评估风险并指导处理，避免母婴出现问题。

早产和胎膜早破 (PROM) 检测有助于识别高风险怀孕。早产检测可确定早产的可能性，胎膜早破 (PROM) 可侦测可侦测胎膜破裂，有助于预防感染疾病并控制早产风险。两者对于早期疗育和改善婴儿结局都至关重要。

早产和胎膜早破（PROMs）检测的未来应用包括提高早期发现率、指导标靶治疗以及个人化治疗方案。未来可能取得进展的途径包括：结合预测性生物标记、建立非侵入性诊断方法以及修订临床指南，以最大程度地降低早产及其相关併发症的发生率。

早产盛行率的不断上升是否会推动早产和胎膜早破检测市场的成长？

由于早产率的上升，早产和胎膜早破（PROM）检测产业必将蓬勃发展。到2021年，美国的早产率将从2020年的10.1%上升至10.5%，届时将有近十分之一的婴儿早产。从2014年到2021年，早产率上升了12%，全球每年约有1500万名婴儿早产。

胎膜早破 (PROM) 导致 2-3% 的妊娠併发症，并在美国造成 30-40% 的早产，凸显了合适的诊断方案的重要性。胎膜早破盛行率的不断上升凸显了对新的诊断工具和干预措施的需求，推动了市场扩张，因为医疗保健提供者正努力有效管理和降低早产及其相关后果的发生率。

高昂的检测费用是否会阻碍早产和胎膜早破检测市场的发展？

高昂的检测费用可能会在一定程度上限制早产和胎膜早破检测市场的发展。检测成本受先进技术和医疗设施的影响，可能成为一大障碍，尤其是在资源匮乏的国家。

例如，在美国，早产管理成本高昂，医疗保健系统每例早产花费6.5万美元，每年高达262亿美元。如此高昂的成本可能会阻碍一些医疗保健相关人员和患者接受高级检测。然而，这可能会推动市场对更经济、更具成本效益的检测方法和创新的需求。降低成本和提高可及性的努力有助于应对这些挑战，同时支持整个产业的成长。

目录

第一章 全球早产和妊娠检测市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球早产及胎膜早破检测市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球早产和胎膜早破检测市场（按类型）

  • 概述
  • 早产筛检
    • 骨盆腔检查
    • 超音波
    • 子宫监测
    • 生物标誌物
  • PROM测试
    • 硝嗪试验
    • 范宁检查
    • 池化
    • 超音波
    • 胎儿纤连蛋白检测
    • 生物标记检测

6. 全球早产及胎膜早破检测市场（依最终用户）

  • 概述
  • 医院
  • 诊断实验室
  • 其他的

7. 全球早产及胎膜早破检测市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

8. 全球早产和胎膜早破检测市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第九章 公司简介

  • Qiagen Sciences, LLC
  • Hologic, Inc.
  • CooperSurgical, Inc
  • Abbott Laboratories
  • Medix Biochemica
  • Sera prognostics
  • Clinical Innovations, LLC
  • Biosynex
  • NX Prenatal, Inc.
  • IQ Products

第十章 附录

  • 相关调查
简介目录
Product Code: 40822

Preterm Birth and PROM Testing Market Valuation - 2026-2032

The preterm birth and PROM (Premature Rupture of Membranes) testing market focuses on the diagnosis and treatment of early births and membrane rupture. The growth is being driven by rising preterm birth rates and advances in diagnostic technologies. Emerging markets are growing as people become more aware of the importance of healthcare. This is likely to enable the market size to surpass USD 2.39 Billion in 2024 to reach a valuation of around USD 4.11 Billion by 2032.

Leading manufacturers in this market are developing novel tests for early detection and management. Non-invasive procedures and point-of-care diagnostics are defining the future. Demand for precise, quick findings drives market growth as healthcare professionals strive to improve patient outcomes and prevent preterm birth problems. The rising demand for Preterm Birth and Prom Testing is enabling the market grow at a CAGR of 7.76% from 2026 to 2032.

Preterm Birth and PROM Testing Market: Definition/ Overview

Preterm birth is defined as a delivery occurring before 37 weeks of pregnancy, which may result in health complications for the baby. PROM Testing Evaluation for Premature Rupture of Membranes (PROM), in which the amniotic sac ruptures before labor begins, assesses risks and guides management to avoid difficulties for both mother and baby.

Preterm birth and PROM (preterm rupture of membranes) testing aid in detecting high-risk pregnancies. Preterm birth testing determines the possibility of early labor, whereas PROM testing detects membrane rupture, which helps to prevent infections and manage preterm delivery risks. Both are critical for early intervention and better infant outcomes.

Future applications of preterm birth and PROM (Premature Rupture of Membranes) testing include increasing early detection, guiding targeted therapies and personalizing treatment approaches. To minimize preterm birth rates and related difficulties, advances will be made by combining predictive biomarkers, establishing non-invasive diagnostic procedures and revising clinical guidelines.

Will Increasing Prevalence of Preterm Births Boost the Preterm Birth and PROM Testing Market Growth?

The rising occurrence of premature births will drive the preterm birth and PROM testing industry. In 2021, the U.S. preterm birth rate increasing to 10.5%, up from 10.1% in 2020, with almost one in every ten babies born preterm. Between 2014 and 2021, the rate climbed by 12%, with roughly 15 million babies born preterm around the world each year.

PROM complicates 2-3% of pregnancies in the United States and is connected with 30-40% of premature births, emphasizing the importance of appropriate diagnostic solutions. This rising incidence highlights the need for new diagnostic tools and interventions, which are driving market expansion as healthcare practitioners strive to effectively manage and reduce the occurrence of preterm births and related consequences.

Will High Cost of Testing Hamper the Preterm Birth and PROM Testing Market?

The high cost of testing may limit the preterm birth and PROM testing market to some extent. Testing costs, which are influenced by advanced technologies and healthcare facilities, can be a considerable barrier, especially in low-resource nations.

In the United States, for example, handling premature births incurs significant costs, with each case costing $65,000 and adding to a $26.2 billion yearly burden on the healthcare system. This hefty expense may dissuade some healthcare practitioners and patients from seeking advanced testing. However, it may increase demand for more economical, cost-effective testing methods and innovations in the marketplace. Efforts to lower costs and enhance accessibility could help to offset these issues while also supporting overall industry growth.

Category-Wise Acumens

Will Increasing Effectiveness in Monitoring Fetal and Uterine Health Drive the Test Type Segment?

Increasing efficacy in monitoring fetal and uterine health will drive the test type sector. Advances in technologies such as ultrasound and biomarker tests improve diagnostic accuracy, enabling for more effective care of preterm deliveries and PROM complications. Enhanced ultrasound capabilities offer more detailed images and insights into fetal development and uterine problems, resulting in better early identification and intervention techniques.

Similarly, advances in biomarker testing enable more exact identification of risk factors and illnesses. As these technologies improve in effectiveness, they are likely to gain traction and drive market expansion. The capacity to better monitor and manage pregnancy issues will result in increasing demand for advanced testing solutions, propelling the test type sector forward.

Will Increasing Wide Range of Diagnostic Tests and Immediate Clinical Interventions Drive the End-User Segment?

The growing number of diagnostic tests and the capacity to deliver quick clinical treatments will propel the end-user segment. Hospitals are well-positioned to profit from advances in diagnostic technologies because of their comprehensive care infrastructure, which includes access to a variety of diagnostic tests and specialists.

Hospitals are the recommended site for these services because they can perform a wide range of diagnostics, such as ultrasounds and biomarker assessments, as well as respond rapidly to preterm birth and PROM complications. As diagnostic capabilities improve and clinical interventions become more advanced, hospitals will continue to increase their use of preterm birth and PROM testing. This trend will continue to boost the end-user segment, cementing hospitals' dominance in this market.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in North America?

Advanced healthcare infrastructure will fuel the market in North America, enabling the region hold major share. According to the US Department of Health and Human Services, by 2020, 96% of non-federal acute care hospitals will have implemented certified electronic health records (EHRs). Additionally, 76% of U.S. hospitals used telemedicine technologies, such as video consultations, to improve patient care and access to services.

This solid infrastructure enables the effective deployment and maintenance of modern diagnostic tests for preterm delivery and PROM. The combination of EHRs and telemedicine enhances data management, diagnostic accuracy and allows for rapid treatments. These technological developments not only improve clinical capabilities, but also promote adoption of testing solutions, resulting in market growth in North America.

Will Increasing Healthcare Investments Drive the Market in Asia Pacific Region?

The Asia Pacific region is expected to exhibit rapid growth in the preterm birth and premature rupture of membranes (PROM) testing market due to increase in healthcare investments. This growth is primarily owing to improvement in healthcare infrastructure which results in better-equipped hospitals and clinics with advanced medical technologies, enhancing the capacity for more sophisticated prenatal care and diagnostic services. Thus, access to advanced diagnostic tools improves the accuracy and timeliness of diagnoses, leading to better outcomes for mothers and infants.

Aso, providing better training and education for healthcare professionals results in improved prenatal care and reduced incidence of preterm births and PROM. In response to the need for improvement in prenatal care, there is high demand for research and development activities in diagnostic tests and treatments, such as new biomarkers or non-invasive tests.

Public health campaigns can raise awareness about the risks of preterm birth and the importance of prenatal care, leading to earlier detection and prevention strategies. Expanding healthcare coverage can make prenatal testing more accessible and affordable for a larger population, increasing the usage of PROM and preterm birth testing services.

The implementation of maternal health programs is projected to facilitate the integration of preterm birth and PROM testing into broader maternal and child health programs, leading to better preventive care and management strategies.

Furthermore, increasing healthcare investments in the Asia Pacific region are expected to significantly boost the market for preterm birth and PROM testing, improving healthcare outcomes for mothers and babies while reducing long-term healthcare costs.

Competitive Landscape

The preterm birth and PROM testing market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the preterm birth and prom testing market include:

Qiagen N.V.

Hologic, Inc.

Cooper Surgical, Inc.

Abbott

Medixbiochemica

Sera Prognostics

Clinical Innovations, LLC

Biosynex

NX Prenatal, Inc.

1Q Products

Latest Developments

In May 2022, Sera Prognostics and the Newborn Foundation launched the Every Mother, Every Baby project. The purpose is to educate physicians, policymakers and public health stakeholders on the importance of validated biomarker-based preterm risk assessment tests, such as Sera's PreTRM test, in improving neonatal health outcomes maternal health outcomes.

In November 2021, Sera Prognostics has partnered with PreemieWorld, GLO Preemies and the Alliance for Black NICU Families to empower and support families affected by preterm birth.

Preterm Birth and Prom Testing Market, By Category

  • Test Type:
  • Preterm Birth Tests
  • Pelvic Exam
  • Ultrasound
  • Uterine Monitoring
  • Biomarker
  • PROM Tests
  • Nitrazine Test
  • Ferning Test
  • Pooling
  • Ultrasound
  • Fetal Fibronectin Test
  • Biomarker Test
  • End-User:
  • Hospitals
  • Diagnostics Laboratories
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRETERM BIRTH AND PROM TESTING MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Preterm Birth Tests
    • 5.2.1 Pelvic Exam
    • 5.2.2 Ultrasound
    • 5.2.3 Uterine Monitoring
    • 5.2.4 Biomarker
  • 5.3 PROM Tests
    • 5.3.1 Nitrazine Test
    • 5.3.2 Ferning Test
    • 5.3.3 Pooling
    • 5.3.4 Ultrasound
    • 5.3.5 Fetal Fibronectin Test
    • 5.3.6 Biomarker Test

6 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY END USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Diagnostic Laboratories
  • 6.4 Others

7 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL PRETERM BIRTH AND PROM TESTING MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Qiagen Sciences, LLC
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Hologic, Inc.
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 CooperSurgical, Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Abbott Laboratories
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Medix Biochemica
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Sera prognostics
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Development
  • 9.7 Clinical Innovations, LLC
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Biosynex
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 NX Prenatal, Inc.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Development
  • 9.10 IQ Products
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Development

10 Appendix

  • 10.1 Related Research